WeChat· 中关村生命科学园公司·· 10 hours agoPickScore69
Novo Nordisk's IcoSema First to Win China Approval for Post-OADs Indication
In brief
Novo Nordisk announced on October 15 that the NMPA has approved the market application of NovoJect (icoSema, insulin icodec and semaglutide injection) for the Post-OADs indication, adding adults with type 2 diabetes inadequately controlled on prior oral antidiabetic drugs. The approval is based on COMBINE 4, a randomized, open-label phase 3b trial enrolling 485 patients that compared once-weekly icoSema with once-daily insulin glargine U100.
Why it matters
The original discloses the sample size, duration and comparator arm of COMBINE 4, allowing readers to benchmark it against marketed basal insulin or GLP-1 regimens.
Source: WeChat · mp.weixin.qq.com